OcuTerra Therapeutics
- 09/11/2021
- Series B
- $35,000,000
Non-Invasive, Transformational Approach to Treating Retinal Disease.
OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity
- Industry Biotechnology Research
- Website https://www.ocuterratx.com/
- LinkedIn https://www.linkedin.com/company/ocuterra-therapeutics/about/
Related People
Kerrie BradyFounder
SENIOR BIOPHARMA EXECUTIVE & BIOTECH ENTREPRENEUR
As a biopharma executive, I have 30+ years of leadership success establishing funding and strategic collaborations that leverage new and emerging technologies to establish development portfolios in competitive markets. My passion for science and talent for business has led to an accomplished career positioning pipeline products to capitalize on partnership opportunities and allocating investments to pave the way for awareness and advocacy among important decision influencers to drive sustainable business growth and solve unmet medical needs.
As a serial entrepreneur with broad expertise across various therapeutic areas, I have a reputation for launching innovative biotech ventures and leading as CEO, COO, and CBO to create sustainable revenue streams and achieve corporate objectives. My understanding of development and commercialization, regulatory compliance, and financial allocation strategies across the product lifecycle enables me to mitigate against potential development issues impacting future market penetration and to translate scientific needs into fundraising and partnership realizations.
I also have a keen ability to develop and communicate value propositions that resonate with key stakeholders, regulatory authorities, payers, providers, legislative decision makers, and investors – my specialty is driving business development by brokering deals that establish market access, identifying the right pipeline products to maximize potential portfolio profits, and bringing those products in for the right price via acquisitions and partnerships. Most recently, as Co-founder and CBO at Centrexion, I raised $150M in funds, secured a landmark deal that quadrupled the industry standard by negotiating a $998M license deal for a Phase 1 novel pain asset to Eli Lilly.
As a leader, I take a collaborative and inclusive approach that brings people together to collectively accomplish goals. I believe in leading by influence rather than by commands, and my global mindset and strong ability to manage cultural sensitivities fosters positive communications that lead to effective collaborations across Asian, European, Australian, and North American markets. Further, I recognize the value of forging and maintaining relationships to give confidence in leadership, and I have a talent for establishing myself as a credible, trusted advisor to partners.